2Aquerreta I, Aldaz A, Giraldez J, et al. Pharmacodynamics of High-dose Methotrexate in Pediatric Patients [ J ].Ann Pharmacother,2002, 36(9):1344-1348.
6Widemann B C, Balis F M, Murphy R F, et al. Carboxypeptidase-G2,Thymidine,and Leucovorin Rrescue in Cancer Patients with Methotrexate-induced Renal Dysfunction [ J ].J Clin Oncol, 1997,15(5):2125-2134.
6Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarooma, results of a randomized cooperative trial ( COSS282 ) with salvage chemotherapy based on histological tumor response [ J ]. J Clin Oncol, 1988, 6(2) : 329-337.
7Brouwers P, Moss H, Reaman G, et al. Central nervous system preventive therapy with systemic high-dose methotrexate versus cranial irradiation and intratheca] methotrexate longitudinal comparison of effects of treatment on intellectual function of children with acute lymphoblastic leukemia [J]. Proc Am Soc Clin Oncol, 1988, (7) : 176- 179.
8Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics [J]. J Clin Invest, 2005, 115(1): 110-117.
9Calpin AJ, Schuetz JD, Masson E, et al. Differences in human B-lineage versus T-lineage lymphoblastie leukemia mechanisms for lineage differences in methotrexate polylufamylation and cytotoxicity [ J ]. Mol Pharmacoi, 1997, 52(1): 155-163.
10Arend von Stackelberg, Reinhard Hartmann, Christoph Buhrer, et al. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia [ J 3. Blood, 2008, 111 ( 5 ) : 2573- 2580.
